Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Available 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Diseases 2Lung Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × zipalertinib × Clear all
NCT07601399 2026-05-22

An EAP Treatment Protocol of Zipalertinib

Taiho Oncology, Inc.

Available
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-05-05

REZILIENT4

Taiho Oncology, Inc.

Phase 3 Active not recruiting
360 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05967689 2026-04-03

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting
220 enrolled

Carcinoma, Lung Diseases

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting
285 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting
284 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡